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Hepatocellular carcinoma · Cabozantinib
Abstract
Background and Aims: The multikinase inhibitor cabozan-
tinib has been approved for hepatocellular carcinoma (HCC) 
previously treated with sorafenib. We report safety and effi-
cacy data of an international, multicenter, real-life cohort of 
patients with advanced HCC treated with cabozantinib. 
Methods: Patients with HCC who were treated with cabo-
zantinib were retrospectively identified across 11 centers in 
Austria, Switzerland, and Germany. Patients’ characteristics, 
adverse events, duration of treatment and overall survival 
(OS) data were analyzed until April 1, 2020. Results: Eighty-
eight patients from 11 centers were included. The predomi-
nant underlying liver diseases were NAFLD/NASH in 26 (30%) 
and hepatitis C infection in 21 (24%) patients. Seventy-eight 
patients (89%) were classified as Barcelona clinic liver cancer 
(BCLC) stage C. Sixty patients (68%) were Child-Pugh A, 
whereas 22 (25%) were Child-Pugh B, respectively. Cabozan-
tinib was used as systemic second- and third-line or later 
treatment in 41 (47%) and 46 (52%) patients, respectively. 
The following best responses under cabozantinib were doc-
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umented: partial response in 6 (7%), stable disease in 28 
(32%), and progressive disease in 28 (32%) patients, respec-
tively. Fifty-two patients (59%) died during follow-up. The 
median OS from start of cabozantinib treatment was 7.0 
months in the entire cohort and 9.7 months in Child-Pugh A 
patients, while Child-Pugh B patients had a median OS of 3.4 
months, respectively. Thirty-seven (42%) patients fulfilled 
the CELESTIAL inclusion and exclusion criteria, showing a 
median OS of 11.1 months. Most common adverse events 
were fatigue (15.6%) and diarrhea (15.6%). Conclusion: 
Cabozantinib treatment was effective, safe, and feasible in 
patients with advanced HCC in patients with compensated 
cirrhosis. Patients in the real-life setting had more advanced 
liver disease – in which 25% of patients were Child-Pugh B. 
However, OS in patients with Child-Pugh A cirrhosis was sim-
ilar to that reported in the phase 3 trial (CELESTIAL).
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Hepatocellular carcinoma (HCC) is the most common 
malignant primary liver cancer and the third leading rea-
son of cancer related death affecting more than half a mil-
lion patients annually [1]. Curative HCC treatment is 
only available in early stages involving local ablative pro-
cedures, surgical resection, or liver transplantation. In pa-
tients not amenable to curative or local therapy as well as 
patients with metastatic disease, systemic treatment is the 
therapy of choice [2].
Since its approval in 2007, only sorafenib has been 
available as systemic treatment option for advanced HCC 
for several years [3]. Within the last 3 years the landscape 
of available treatment options has profoundly changed 
[4]. The TKI lenvatinib was noninferior to sorafenib in 
the first-line setting and the combination of the PD-L1 
antibody atezolizumab and bevacizumab showed superi-
ority to sorafenib and is considered the new standard of 
care also in Europe with the European Medical Agency 
(EMA) approval in November 2020 [5, 6]. Several drugs 
have been approved for second-line treatment of HCC by 
the United States Food and Drug Administration (FDA) 
and EMA including regorafenib, ramucirumab, and 
cabozantinib [7–10], whereas nivolumab, the combina-
tion of nivolumab and ipilimumab and pembrolizumab 
have only been approved by the FDA and not in Europe 
due to missing or negative phase 3 trial results [11–17].
In contrast to cabozantinib which has been approved 
for all sorafenib pretreated patients in the second- and 
third-line setting [18], ramucirumab use is restricted to 
patients with alpha-fetoprotein (AFP) levels >400 ng/mL 
and regorafenib treatment is limited to sorafenib-tolerant 
patients. However, data of phase 3 trials are not always 
easily applicable in the real-life setting and patient co-
horts differ significantly from those in everyday clinical 
practice. In all mentioned trials, only patients with well-
compensated cirrhosis (Child-Pugh A) were included. 
Notably, many patients treated in real life have more ad-
vanced liver disease, namely Child-Pugh B or even C. For 
these patients, data concerning efficacy of the indicated 
drugs are scarce. Only for sorafenib treatment, a large 
prospective registry is published, which reported similar 
efficacy of sorafenib in Child-Pugh A patients compared 
to the phase 3 trial. However, Child-Pugh B and C pa-
tients had a significant worse outcome [19]. A subgroup 
analysis from the registry showed no benefit for ramuci-
rumab in comparison to placebo for Child-Pugh B pa-
tients [20]. For cabozantinib, no larger real-life data set 
has been reported. In the current article, we evaluated ef-
ficacy and safety of cabozantinib in a multicenter, inter-
national, real-life cohort of HCC patients.
Patients and Methods
Study Design and Selection of Patients
This was a retrospective study of patients treated with cabozan-
tinib across 11 centers in Germany, Austria, and Switzerland. Pa-
tients with histologically or radiologically confirmed HCC who 
received cabozantinib as systemic treatment until April 2020 were 
eligible for inclusion into the analysis. Patients’ data including his-
tory of the disease, treatment course, laboratory results, radiologi-
cal data, and follow-up were collected retrospectively from patient 
files. The study was performed in accordance with the 1975 Dec-
laration of Helsinki. The retrospective analysis was approved by 
the local Ethics Committee (SGI03/18, Amendment 01/19) as well 
as the Ethics Committees of the individual centers.
Assessments
Electronic hospital charts were retrospectively analyzed for 
baseline demographic data and laboratory results. Radiological re-
sponse was recorded by computed tomography (CT) or magnetic 
resonance imaging (MRI) at baseline, 6–12 weeks after treatment 
initiation, and about every 2–3 months thereafter according to the 
local guidelines. Tumor response was assessed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 [21] 
or modified RECIST [22] (according to centers preference). Side 
effects were recorded at every visit and graded according to the 
Common Terminology Criteria for Adverse Events (CTCAE) ver-
sion 4.0 [23].
Cabozantinib
Cabozantinib is approved by the EMA, the Swissmedic from 
Switzerland, and the FDA for the treatment of patients with HCC 
who have been previously treated with sorafenib. The recom-
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mended dose for cabozantinib in HCC is 60 mg orally once daily. 
Dose delays or reductions were made based on toxicity and were 
suggested as 40 or 20 mg as given in the summary of product char-
acteristics.
Statistical Analysis
This study was designed as a retrospective cohort study. All 
patients were followed until death or last contact. The primary end 
point was overall survival (OS) and secondary end points included 
progression-free survival (PFS), response rate, and safety.
Data on baseline characteristics, radiological tumor response, 
and side effects were summarized using descriptive statistics. Con-
tinuous variables are shown as median and full range and categor-
ical variables are reported as frequencies and percentages. Median 
duration of treatment was defined as time from the date of the first 
administration until the date of last documented administration. 
Patients still receiving cabozantinib at data cutoff were censored. 
Patients with at least one follow-up imaging assessment were eval-
uable for radiological response.
Data from patients, who died without radiologically confirmed 
tumor progression, were censored at the date of last radiological 
assessment or death. PFS was defined as the time from the date of 
first cabozantinib administration until radiological disease pro-
gression or death, whatever occurred first. Patients still alive and 
without radiologically confirmed progression at the date of last 
contact or data cutoff were censored. OS was defined as the time 
from start of cabozantinib until the date of death. Survival curves 
were calculated using the Kaplan-Meier method and compared by 
means of the log rank test. To analyze prognostic parameters a uni- 
and multivariate Cox regression model with forward stepwise like-
lihood ratio was performed. Statistical analyses were performed 
with SPSS (Version 27.0, IBM, New York, NY, USA) and Graph-
Pad Prism 8.0 (GraphPad Software, La Jolla, CA, USA). Differ-
ences between different patient cohorts were determined using the 
nonparametric Wilcoxon-Mann-Whitney and Kruskal-Wallis 
tests or Fisher’s exact text. For subanalysis of multiple compari-
sons, the Bonferroni correction was used. p values <0.05 were con-
sidered to be significant.
Results
Patients
Eighty-eight patients from 11 centers (1 Austrian cen-
ter, 1 Swiss center, and 9 German centers) were included. 
To avoid a selection bias, we included every consecutive 
patient treated with cabozantinib retrospectively in the 
individual centers, no patients were excluded from analy-
sis.
Individual patients had started cabozantinib treat-
ment in the time from 16 July 2015 to 22 February 2020. 
Data cutoff for the analysis was 7th April 2020. Seventy-
six patients (86%) were male and the median age was 66 
years (range 25–84 years). Main baseline characteristics 
are shown in Table 1. Most patients (n = 60, 68%) were 
Child-Pugh stage A, whereas 22 (25%) were Child-Pugh 




Gender, m/f (%) 76 (86.4)/12 (13.6)
Age, median, range 65.6 (25–84)
Etiology of liver disease
Alcohol, n (%) 18 (20.5)
Hepatitis C, n (%) 21 (23.9)
Hepatitis B, n (%) 7 (8.0)
NASH, n (%) 26 (29.5)
Cryptogenic/unknown, n (%) 16 (18.1)
BCLC stage
A, n (%) 1 (1.1)
B, n (%) 8 (9.1)
C, n (%) 78 (88.6)
D, n (%) 1 (1.1)
MVI, n (%) 32 (36.4)
EHS, n (%) 60 (68.2)
Child-Pugh score
A, n (%) 60 (68.2)
B, n (%) 22 (25.0)
C, n (%) 1 (1.1)
ALBI grade
1, n (%) 23 (26.1)
2, n (%) 60 (68.2)
3, n (%) 4 (4.5)
MELD, median, range 9 (6–20)
ECOG
0, n (%) 16 (18.2)
1, n (%) 61 (69.3)
2, n (%) 10 (11.4)
Prior treatment
Resection, n (%) 34 (38.6)
Local ablation,* n (%) 13 (14.8)
Loco-regional (TACE/SIRT), n (%) 37 (42.0)/29 (33.0)
Liver transplantation, n (%) 3 (3.4)
Previous sorafenib, n (%) 81 (92.0)






BMI, median, range 23.5 (14–42)
ALT, U/L, median, range 47 (12–498)
AST, U/L, median, range 80.5 (22–544)
Bilirubin, mg/dL, median, range 0.7 (0.2–4.8)
Albumin, mg/dL, median, range 3.6 (1.9–5.1)
INR, mean, median, range 1.12 (0.9–2.8)
Creatinine, mg/dL, median, range 0.89 (0.3–1.9)
CRP, mg/dL, median, range 2.1 (0.2–16.4)
AFP, ng/mL, median, range 98 (0–127,135)
AFP >400 ng/mL, n (%) 34 (38.6)
NASH, nonalcoholic steatohepatitis; BCLC, Barcelona clinic liver 
cancer; MVI, macrovascular invasion; EHS, extrahepatic spread; 
MELD, model of end stage liver disease; ECOG, performance status 
Eastern Conference Oncology Group; TACE/SIRT, transarterial 
chemoembolization/selective internal radiotherapy; BMI, body mass 
index; ALT, alanine aminotransferase, AST, aspartate aminotransferase; 
INR, internationalized ratio; CRP, C-reactive protein; AFP, alpha-
fetoprotein; ALBI, albumin-bilirubin; RFA, radiofrequency ablation; 
MWA, microwave ablation. * Including RFA and MWA.




stage B and one patient (1%) was Child-Pugh stage C, in 
the remaining 5 patients Child-Pugh stage was not re-
ported.
Eighty-one patients (92%) had received sorafenib be-
fore cabozantinib treatment (median treatment time 287 
days, range 8–2,320 days). Twenty-eight patients (32%) 
had obtained 2 systemic therapy lines before initiation of 
cabozantinib and 15 (17%) patients had 3 previous ther-
apy lines, respectively. Three patients (3%) even had 4 
previous therapy lines. Twenty-five patients received at 
least one additional systemic anticancer drug following 
cessation of cabozantinib treatment. Fifty-two patients 
(59%) died during follow-up. Median follow-up time af-
ter start of cabozantinib was 4.8 months with a range of 
0.7–18.4 months.
Efficacy
At last contact, 69 patients (78%) had stopped cabo-
zantinib treatment due to any form of disease progression 
as described above. Thirteen patients (15%) were still on 
treatment and 6 patients (7%) were lost to follow-up. Me-
dian time on cabozantinib was 69 days with a range of 
3–437 days.
Overall, 62 patients had at least one follow-up imaging 
and assessment of tumor response was feasible. In 26 pa-
tients (30%) response could not be assessed. Eighteen 
















Median overall survival 210 days (95% CI 150–269)
88 62 35 20 9 2 1


















Patients at risk 88 43 26 11 7 2 1
Median progression free survival 102 days (95% CI 82–121)
Fig. 1. a, b Kaplan-Meier analysis of OS 
and PFS. OS was defined as the time from 
starting cabozantinib to death from any 
cause and PFS as the time from starting 
cabozantinib to radiographic progression 
or death from any cause. Tick marks indi-
cate censored data. OS, overall survival; 
PFS, progression-free survival; CI, confi-
dence interval.
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(20%) patients died before the first staging examination 
could be performed. These patients had a median OS of 
51 days with a range of 21–89 days. Of the 18 patients, 16 
were male (89%), the etiology of liver disease was mainly 
NAFLD/NASH (n = 7, 39%), and 15 (83%) of the indi-
cated patients had underwent prior sorafenib therapy. 
Seven of the 18 patients (39%) were Child-Pugh B and 8 
(44%) patients had an AFP level above 400 ng/mL. In 
these patients, median duration of cabozantinib treat-
ment was 48 days with a range of 8–92 days. In 4 patients 
the treatment regimen was changed before first tumor as-
sessment could be performed, in 3 patients cabozantinib 
was stopped on patients wish due to diarrhea grade 3 in 
one case and fatigue grade 2 in 2 cases, one patient had 
stopped without further documented reasons, and 4 pa-
tients were lost to follow-up.
None of the assessed patients showed a complete re-
sponse (CR), 6 patients (7%) had a partial response (PR), 
28 patients (32%) showed stable disease, and 28 patients 
(32%) had progressive disease (PD), respectively. Taken 
together, we found an overall response rate (ORR) of 7% 
and a disease control rate (DCR) of 39%. Based on the 
entire cohort, the median PFS was 102 days (3.4 months) 
(95% CI 82–121 days) and the OS after start of cabozan-
tinib was 210 days (7.0 months) (95% CI 150–269 days) 
as depicted in Figure 1a and b and Table 2.
Patients with only one prior systemic treatment line 
tended to have a longer median OS (244 days, 95% CI 
96–392 days) (8.1 months) than patients with 2 or more 
systemic treatment regimens before initiation of cabo-
zantinib (209 days, 95% CI 140–278 days) (7.0 months). 
However, the difference was not statistically significant 
(p = 0.88) (for treatment regimen before and after cabo-
zantinib, see online suppl. material; for all online suppl. 
material, see www.karger.com/doi/10.1159/000515490).
OS did not differ among patients who received previ-
ous treatment with sorafenib compared to patients with-
out sorafenib therapy before initiation of cabozantinib 
(p = 0.277). Additionally, no differences in OS were found 
between patients with or without a history of locoregion-
al therapies in general (p = 0.637) and TACE (p = 0.590) 
or radioembolization (p = 0.575) in particular.
By a close margin, there was no statistically significant 
difference in OS between patients with AFP levels >400 
mg/nL compared to patients with low AFP levels (p = 
0.054). However, median OS was shorter (147 days, 95% 
CI 81–213 days) (4.9 months) in patients with AFP levels 
>400 mg/nL compared to patients with lower AFP levels 
(292 days, 95% CI 157–427 days) (9.7 months).
Patients with Barcelona clinic liver cancer (BCLC) C 
stage had a median OS of 199 days (95% CI 135–263 days) 
(6.6 months) compared to patients with less advanced 
disease (BCLC B and BCLC A), who had a median sur-
vival of 423 days (95% CI 232–614 days) (14.1 months), 
respectively (p = 0.056). The median OS for patients with 
PR or SD(stable disease) was 423 days (95% CI 264–582 
days) (14.1 months) and significantly longer compared to 
patients with PD (187 days; 95% CI of 148–226 days) (6.2 
months) (p = 0.007) as best response, respectively (Fig. 2).
We evaluated the whole cohort for patients fulfilling 
the CELESTIAL inclusion and exclusion criteria and in-
cluded the patients whose information was fully available. 
We identified 37 (42%) patients. The patients fulfilling 
the CELESTIAL inclusion criteria had a median OS of 
333 days (95% CI 224–441) compared to the patients who 
did not fulfill the CELESTIAL inclusion criteria who had 
a median OS of 192 days (95% CI 97–286). The difference 
among the 2 cohort was not statistically significant, but 
showed a clear trend and was not significant in this cohort 
most probably due to small sample size (11.1 vs. 6.4 
months, p = 0.06). PFS did not significantly differ among 
the 2 groups (106 days [95% CI 56–155] vs. 98 days [95% 
CI 82–114], indicating 3.5 vs. 3.2 months, p = 0.4339).
Safety
Recommended starting dose of cabozantinib in pa-
tients with HCC is 60 mg. In our cohort, 37 patients (42%) 
received 60 mg of cabozantinib, whereas 23 patients 
(26%) started with 40 mg and 28 patients (32%) had 20 
mg as initial dosage. Thirty-four patients (39%) had dose 
reductions during treatment course. In 54 (61%) patients, 
no reductions in dosing were reported. The reduced dos-
es were 20 mg in 17 patients (19%) and 40 mg in 15 pa-
Table 2. Radiological response and survival data
Parameter Patients
Best documented response
CR, n (%) 0
PR, n (%) 6 (6.8)
SD, n (%) 28 (31.8)
PD, n (%) 28 (31.8)
NA, n (%) 26 (29.5)
DCR, % 38.6
PFS, median days (95% CI), month 102 (82–121), 3.2 months
OS, median days (95% CI), month 210 (150–269), 6.8 months
PFS, progression-free survival; OS, overall survival; CR, 
complete response; PR, partial response; SD, stable disease; PD, 
progressive disease; NA, not evaluable; DCR, disease control rate.




tients (17%). In 21 patients (24%) dose escalation was re-
ported during treatment. In 45 patients (51%) at least one 
adverse event (AE) was reported. Four patients stopped 
cabozantinib before the first staging, all on patients’ wish. 
One patient developed diarrhea grade 3 and 2 patients 
developed fatigue grade 2. The incidence of the individu-
al AEs is shown in Table 3.
We further analyzed the 28 patients who started with 
20 mg and compared these patients to the rest of the co-
hort. We found a comparable adverse event rate (55 vs. 
48%) and no difference in ECOG, etiology of liver disease 
or Child-Pugh stage distribution, respectively. However, 
patients with 20 mg as a starting dose had significantly 
higher likeliness to be in a later treatment line (>2 previ-
ous treatment lines n = 21 [75%] in the 20 mg group vs. 
n = 26 [43%] in the remaining cohort, p = 0.006).
Efficacy and Safety according to Child-Pugh Stage
In real life, many patients at need for systemic treat-
ment have more advanced cirrhosis and are formally clas-
sified as Child-Pugh stage B. However, these patients 
were excluded in the CELESTIAL trial, a common prac-
tice in HCC trials [8]. Therefore, safety and efficacy data 
in patients with impaired liver function is desirable. In 
this cohort, most patients (n = 60, 68%) were Child-Pugh 
stage A. However, 22 (25%) were Child-Pugh stage B and 
one patient (1%) was Child-Pugh stage C.
We compared PFS and OS among patients with com-
pensated liver disease (Child-Pugh A) and more ad-
vanced disease, mainly Child-Pugh B patients. Patients 
stratified for Child-Pugh A cirrhosis had a median OS of 
292 days (95% CI 171–429 days) (9.7 months). Patients 
with stage Child-Pugh B7 only showed a median OS of 























34 30 23 14 7 3 1
Median survival 423 vs. 187 days
log rank HR 2.349 (CI 95% 1.1457–4.817)
p = 0.007
28 25 11 6 2 1 1
Fig. 2. Kaplan-Meier analysis of OS accord-
ing to response. OS was defined as the time 
from starting cabozantinib to death from 
any cause. PR + SD are patients with partial 
response or stable disease compared to pa-
tients with PD. Curve comparison by log 
rank test. Tick marks indicate censored 
data. OS, overall survival; PD, progressive 
disease; PR, partial response; CI, confi-
dence interval; HR, hazard ratio; SD, stable 
disease.





Diarrhea 15 (16.5) 8 (8.8)
Fatigue 15 (16.5) 4 (4.4)
Loss of appetite 10 (11) 1 (1.1)
Nausea 6 (6.6) 3 (3.3)
Palmar-plantar erythrodysesthesia 6 (6.6) 1 (1.1)
Vomiting 3 (3.3)
Rash 3 (3.3)
Hypertension 2 (2.2) 1 (1.1)
Weight loss 2 (2.2)
Hypocalcemia 1 (1.1) 1(1.1)
Nephrotic syndrome 1 (1.1) 1 (1.1)
Stomatitis 1 (1.1) 1 (1.1)
Vertigo 1 (1.1)
Bone pain 1 (1.1)
Hyperbilirubinemia 1 (1.1)
Sore mouth 1 (1.1)
Abdominal pain 1 (1.1)
Cramps 1 (1.1) 1 (1.1)
Leucocytoclastic vasculitis 1 (1.1)
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210 days (95% CI 52–368 days) (7.0 months). In contrast, 
patients with a more advanced liver disease (Child-Pugh 
B8, B9, and C) had a much less favorable median OS of 
101 days (95% CI of 73–129 days) (3.4 months). The dif-
ference concerning OS was statistically significant (p < 
0.001). Figure 3. PFS was median 98 days (79–116) in 
Child-Pugh A and median 94 days (73–114) in Child-
Pugh B.
Safety analysis showed 26 documented AEs in Child-
Pugh A patients (43.3%) compared to 16 in Child-Pugh 
B patients (72.7%), which was significantly different (p = 
0.017). From the 4 patients who stopped cabozantinib 
treatment early due to an AE, 2 were Child-Pugh B. In the 
Child A cohort, 33 patients out of 60 (55%) started with 
reduced dose (20 or 40 mg) and in the Child B cohort, 18 
out of 22 patients (81.8%) (p = 0.04). However, during 
treatment, there was no significant difference in patients 
with dose reduction (40 vs. 36.3%, p = 0.84).
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60 47 30 16 8 3 1
22 11 4 3 1 1 1
log rank HR 3.0 (CI 95% 1.316–7.010)
Table 4. Univariate and multivariate analyses of parameters associated with OS
Parameter Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Female gender 0.620 0.287–1.339 0.224
Age ≤65 years 1.045 0.587–1.860 0.882
BCLC stage 0.480 0.169–1.364 0.168
ALBI score 2.935 1.618–5.323 <0.001
AFP >400 ng/mL 1.8 0.981–3.303 0.058
Child-Pugh B/C versus A 2.027 1.273–3.228 0.003 2.756 1.409–5.391 0.003
Stable disease/PR versus PD 0.413 0.192–0.886 0.023 0.442 0.204–0.961 0.039
Prior sorafenib therapy 0.535 0.189–1.508 0.273
2nd-line cabozantinib versus later 0.908 0.513–1.605 0.739
CI, confidence interval; HR, hazard ratio; BCLC, Barcelona clinic liver cancer; ALBI score, albumin-bilirubin score; AFP, alpha-
fetoprotein; PR, partial response; PD, progressive disease; OS, overall survival. Values in bold signify p < 0.05.
Fig. 3. Kaplan-Meier analysis of OS accord-
ing to Child-Pugh stage. OS was defined as 
the time from starting cabozantinib to 
death from any cause. Comparison of pa-
tients with Child-Pugh stage A versus 
Child-Pugh stage B. Curve comparison by 
log rank test. Tick marks indicate censored 
data. OS, overall survival; CI, confidence 
interval; HR, hazard ratio.




Factors Associated with Survival
Known predictors of survival in patients with HCC in-
clude liver function and AFP levels. The variables gender, 
age (≤65 years vs. >65 years) [24], the BCLC stage, AFP 
levels (≤400 ng/mL vs. >400 ng/mL) [25], the albumin-
bilirubin (ALBI) score [26], the treatment response, prior 
sorafenib therapy, and the treatment line [27] were in-
cluded in a univariate cox regression model. Further-
more, all factors from univariate analysis with a p value 
<0.1 were included in the multivariate model. As shown 
in Table 4, only the Child-Pugh stage and the treatment 
response were independently associated with OS.
Discussion
Cabozantinib has been the first drug for second-line 
and third-line treatment of sorafenib pretreated HCC pa-
tients. Furthermore, following first-line systemic treat-
ment cabozantinib is the only drug in this setting which 
can be prescribed to all patients irrespective of baseline 
AFP levels or tolerability of sorafenib treatment. This dif-
ferentiates it from ramucirumab and regorafenib [7, 8, 
28]. Especially in the EMA area in Europe, where nivolum-
ab and pembrolizumab have not been approved for HCC 
due to negative phase 3 trials [11, 29], it is at least formal-
ly the standard drug for sorafenib pretreated HCC pa-
tients.
It is well known that patients in real-life more often 
have advanced liver disease than patients included in in-
terventional trials. In our cohort of patients from several 
centers in Europe, we found a substantial number of pa-
tients with more advanced liver disease, namely Child-
Pugh B patients, who were treated with cabozantinib. 
More advanced liver disease is associated with a poorer 
overall prognosis and also the benefit from systemic treat-
ment with TKIs such as sorafenib and the VEGFR2 di-
rected antibody ramucirumab seem to be much less in 
patients with Child-Pugh B and C cirrhosis compared to 
Child-Pugh A cirrhosis [19, 20]. In our cohort, patients 
with Child-Pugh B7 had a worse outcome than Child-
Pugh A patients, but a more favorable prognosis than pa-
tients with more advanced disease, indicating that these 
patients still benefit from systemic treatment. On the oth-
er hand, patients with more advanced cirrhosis should 
not receive cabozantinib as recommend by current guide-
lines [2]. Similar to sorafenib, hepatobiliary elimination 
appears to be the major route of elimination of cabozan-
tinib and its metabolites. Although metabolized, cabo-
zantinib appears to be the pharmacologically active circu-
lating analyte [30]. Data on cabozantinib in patients with 
impaired renal or hepatic function are scarce; pharmaco-
kinetics studies were done for single dose 60 mg/daily. 
Cabozantinib plasma exposures were minimally in-
creased (<30%) in subjects with mild- or moderate-renal 
impairment compared to those with normal-renal func-
tion. Exposures to cabozantinib in subjects with mild and 
moderate hepatic impairment were moderately increased 
compared to subjects with normal-hepatic-function [31].
As mild to moderate hepatic impairment nearly dou-
bles exposure rates, severe hepatic impairment (i.e., 
Child-Pugh B and C cirrhosis) could profoundly hamper 
the drug metabolism leading to even much higher drug 
concentrations and potentially more adverse effects. Re-
cently, El-Khoueiry and colleagues [32] published an ab-
stract of a subgroup analysis of patients from CELESTIAL 
who deteriorated to Child-Pugh B 8 weeks after starting 
cabozantinib but still showed an OS of 8.5 months. Con-
sidering our patients with Child-Pugh B7 with an OS of 7 
months, this is comparable, especially considered that at 
study entry, 75% of patients had Child-Pugh A6 and 25% 
had A5 in CELESTIAL.
The OS in our cohort in the subset of patients with 
only Child-Pugh A cirrhosis was comparable to the phase 
3 CELESTIAL trial with a median OS of 9.7 months. 
Moreover, patients in our cohort who formally fulfilled 
the inclusion criteria for the CELESTIAL trial had a me-
dian OS of 11.1 months which is even longer than the 
median OS in the CELESTIAL registry trial of 10.2 
months [8].
Patients with higher AFP levels who have generally a 
poorer prognosis tended to have a shorter median OS un-
der treatment with cabozantinib compared to patients 
with lower AFP levels. In our cohort, prognosis of pa-
tients with or without previous locoregional pretreat-
ment did not differ, which is in line with the CELESTIAL 
trial, where efficacy of cabozantinib was also irrespective 
of pretreatment with TACE [33]. Recommended cabo-
zantinib starting dose is 60 mg daily. In the CELESTIAL 
trial, the average cabozantinib dose administered to the 
patients was 38.5 mg/days [8]. In our patients <50% re-
ceived 60 mg as starting dose. The other patients started 
with a daily dose of 40 mg or even only 20 mg. Neverthe-
less, further dose reductions were done in nearly 40% of 
patients. Of note, in >20% of patients drug dose was in-
creased during treatment course. We could not find any 
difference in OS or PFS in the patients who started with 
lower cabozantinib dosage than patients who stated with 
the standard dose of 60 mg. As this was a retrospective 
clinical cohort, we only can speculate about the reasons 
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for starting with lower doses; however, mainly the con-
sideration would be to reduce side effects in the beginning 
to rise treatment adherence. The common practice to 
start with reduced doses has led to clinical trials such as 
the CABORISE trial which investigates planned dose es-
calation in HCC patients (NCT 04522908). AEs were also 
commonly reported in our patients and were completely 
comparable to AEs reported in CELESTIAL, however, 
much less frequent (e.g., diarrhea 54 vs. 17%). We can 
only speculate about the reason, however, as documenta-
tion of adverse advents is mandatory in trials but not in 
real-life most probably not all adverse events in number 
were documented. However, there were no new safety 
signals in this study especially not in advanced liver dis-
ease patients.
Tovoli and colleagues [34] published an abstract eval-
uating 52 patients from different centers treated with 
cabozantinib in hepatocellular in real-life, which was the 
only data we found on this topic. They only included pa-
tients with compensated liver disease (e.g., only Child A 
patients) and found a median OS of 12.9 months with 
comparable efficacy and safety to the CELESTIAL trial. 
This is in accordance to our data and underlines the find-
ing of good efficacy of cabozantinib in a real-world setting 
in patients with preserved liver function.
Several drugs have shown less effectiveness in HCC in 
real-life compared to trial data, especially in advanced 
stages of cirrhosis [35, 36], the main reason might be the 
narrow eligibility criteria in drug trials making the results 
not comparable to the HCC population. In this subset of 
patients in a real-life setting, cabozantinib showed com-
parable efficacy (OS beyond 9 months in Child-Pugh A 
patients) and safety in patients with preserved liver func-
tion and confirmed the reported findings of the CELES-
TIAL trial.
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